GLUE
NASDAQ · Biotechnology
Monte Rosa Therapeutics Inc
$15.88
+0.17 (+1.08%)
Open$15.82
Previous Close$15.71
Day High$16.12
Day Low$15.65
52W High$25.77
52W Low$4.12
Volume—
Avg Volume2.19M
Market Cap1.34B
P/E Ratio—
EPS$-1.46
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+142.1% upside
Current
$15.88
$15.88
Target
$38.45
$38.45
$28.40
$38.45 avg
$50.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 124.67M | 401.98M | 400.93M |
| Net Income | -38,939,634 | -29,192,444 | -34,329,564 |
| Profit Margin | -31.2% | -7.3% | -8.6% |
| EBITDA | -46,225,114 | -51,685,540 | -47,809,490 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 |
| Rev Growth | — | +22.8% | -9.2% |
| Debt/Equity | — | 0.43 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |